NDA 021539 · Apotex
Acetadote
Acetylcysteine · Intravenous · Antidote; Antidote for Acetaminophen Overdose; Mucolytic
Priority reviewOrphanLast checked: Nov 21, 2026Latest source record: Jul 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jan 23, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
587
113 Phase 3, 40 recruiting
FAERS reports
9,625
8,567 serious, 1,796 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 31, 2025.
Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 ).
Mechanism: Acetylcysteine has been shown to reduce the extent of liver injury following acetaminophen overdose. Acetaminophen doses of 150 mg/kg or greater have been associated with hepatotoxicity. Acetylcysteine probably protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite of acetaminophen.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 26, 2024 Supplement 19 · Efficacy OrphanLabelLetter
- Jan 23, 2004 Original approval · Type 3 - New Dosage Form · priority review OrphanReviewLetterLabel
1 products under this application
- ACETADOTE · ACETYLCYSTEINE 6GM/30ML (200MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetylcysteine" as an intervention, any sponsor and status, largest first.
- Therapeutics for Moderate and Severe DenguePivotal-lookingNot yet recruiting
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT07543458 · 8,800 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2030
Drug: Placebo; Dexamethasone and 2 more · For: Dengue; Severe Dengue; Mosquito-Borne Diseases and 5 more
Sites: Chittagong, Bangladesh; Dhaka, Bangladesh; São Paulo, Brazil · 18 sites in all
- Prevention of Serious Adverse Events Following AngiographyPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01467466 · 5,177 participants · Start Oct 7, 2013 · Primary completion Sep 29, 2017
Drug: IV isotonic saline; IV isotonic bicarbonate and 2 more · For: Acute Renal Failure; Kidney Disease; Coronary Artery Disease
Sites: Tucson, Arizona; Little Rock, Arkansas; Palo Alto, California · 54 sites in all
- Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract InfectionsPivotal-lookingCompleted
Reckitt Benckiser LLCIndustry
NCT01537081 · 2,810 participants · Start Sep 2011 · Primary completion Mar 2012
Drug: Mucinex; Immediate-release Guaifenesin and 1 more · For: Acute Upper Respiratory Tract Infection
Sites: Hoover, Alabama; Bell Gardens, California; Harbor City, California · 43 sites in all
- The Acetylcysteine for Contrast-Induced Nephropathy TrialPivotal-lookingCompleted
Hospital do CoracaoAcademic, hospital or other
NCT00736866 · 2,300 participants (planned) · Start Aug 2008 · Primary completion Jul 2010
Drug: Acetylcysteine; Placebo · For: Acute Kidney Failure
Sites: São Paulo, Brazil
- Impact of Timing of Premedication on Mucosal Visibility During Endoscopy-A Randomized Controlled TrialPivotal-lookingCompleted
Asian Institute of Gastroenterology, IndiaAcademic, hospital or other
NCT06581783 · 1,200 participants · Start Dec 1, 2024 · Primary completion Feb 18, 2025
Drug: Simethicone plus NAC · For: Endoscopy, Digestive System
Sites: Hyderabad, India
- Inflammatory Regulation Effect of NAC on COVID-19 TreatmentPivotal-lookingStatus unknown
Dr. Tariq AlhawassiAcademic, hospital or other
NCT04455243 · 1,180 participants (planned) · Start Aug 1, 2020 · Primary completion Aug 30, 2021
Drug: N-Acetyl cysteine; Placebo · For: COVID-19
- Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTIPivotal-lookingCompleted
Reckitt Benckiser Inc.Industry
NCT01202279 · 1,179 participants · Start Oct 2009 · Primary completion Apr 2010
Drug: Guaifenesin · For: Acute Upper Respiratory Track Infection
Sites: Mesa, Arizona; Carmichael, California; Fresno, California · 24 sites in all
- A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function RecoveryPivotal-lookingNot yet recruiting
Open Source Pharma FoundationAcademic, hospital or other
NCT07136987 · 1,104 participants (planned) · Start Jan 2026 · Primary completion Jan 2031
Drug: Metformin · For: Tuberculosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea800
- off label use680
- drug ineffective679
- pneumonia651
- pyrexia520
- fatigue468
- nausea453
- diarrhoea379
- vomiting342
- death333
- cough323
- hypertension318
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 176 |
| 2005 | 136 |
| 2006 | 154 |
| 2007 | 126 |
| 2008 | 194 |
| 2009 | 190 |
| 2010 | 270 |
| 2011 | 284 |
| 2012 | 281 |
| 2013 | 166 |
| 2014 | 204 |
| 2015 | 285 |
| 2016 | 288 |
| 2017 | 273 |
| 2018 | 430 |
| 2019 | 517 |
| 2020 | 597 |
| 2021 | 774 |
| 2022 | 799 |
| 2023 | 929 |
| 2024 | 872 |
| 2025 | 951 |
| 2026 | 728 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Acetadote* (Acetylcysteine*) · HCPCS J0132
2024 spending
$679
Beneficiaries
190
769 claims
Per beneficiary
$4
2024 ASP limit $0.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $333 |
| 2021 | $121 |
| 2022 | $281 |
| 2023 | $396 |
| 2024 | $679 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interventions for paracetamol (acetaminophen) overdose.
Chiew AL, Gluud C, Brok J, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis.
Viña I, Viña JR, Carranza M, et al. · Nutrients 2025 · Systematic Review, Meta-Analysis
- Comparison of two-bag and three-bag acetylcysteine regimens in the treatment of paracetamol poisoning: a systematic review and meta-analysis.
Nakatsu L, Lopez JR, Garcia CM, et al. · Clin Toxicol (Phila) 2025 · Systematic Review, Meta-Analysis
- Antioxidants for female subfertility.
Showell MG, Mackenzie-Proctor R, Jordan V, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Systematic Review
- Pharmacotherapy for trichotillomania.
Hoffman J, Williams T, Rothbart R, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning?
Buckley NA, Whyte IM, O'Connell DL, et al. · J Toxicol Clin Toxicol 1999 · Comparative Study, Meta-Analysis
Sponsor: Apotex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.